NCT05693701 Multicomponent Intervention Study- Blood Donors With High Cholesterol
| NCT ID | NCT05693701 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | Lipid Metabolism Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-02-27 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-02-27 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose and objective of this study is to improve cholesterol treatment among blood donors with FH (Familial Hypercholesterolemia).
Eligibility Criteria
Inclusion Criteria: * Blood donors from Carter BloodCare with high cholesterol meeting MEDPED FH criteria * Age 18 to 75 years Exclusion Criteria: * Currently taking medication to lower cholesterol * Taking any medication that can interact with statins * Pregnancy * Identified secondary cause of elevated lipids * Chronic liver disease or significantly elevated liver function tests (\> 3 times upper limit)
Contact & Investigator
Amit Khera, MD
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT05693701 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lipid Metabolism Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05693701 currently recruiting?
Yes, NCT05693701 is actively recruiting participants. Contact the research team at Amit.Khera@UTSouthwestern.edu for enrollment information.
Where is the NCT05693701 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT05693701 clinical trial?
NCT05693701 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Amit Khera, MD at University of Texas Southwestern Medical Center. The trial plans to enroll 100 participants.